Two-year real-world outcome data from a single tertiary centre shows reduced ustekinumab persistence in a non-bio-naïve Crohn's disease cohort with penetrating disease, -ostomies and sarcopenia
来自一家三级医疗中心的两年真实世界结果数据显示，在患有穿透性克罗恩病、造口术和肌肉减少症的非生物制剂初治克罗恩病患者队列中，乌司奴单抗的持续使用率降低。
期刊:Therapeutic Advances in Chronic Disease
影响因子:2.8
doi:10.1177/20406223231189072
Inniss, Saskia; Fragkos, Konstantinos C; Whitley, Lisa; Wimpory, Rachel; Rebello, Eleanor; Lisboa, Ana; Khetan, Tanvi; Hassan, Jasmine; Simpson, Kate; Bhagwanani, Anisha; Vega, Roser; Parisi, Ioanna; Harrow, Paul; Seward, Edward; McCartney, Sara; Bloom, Stuart; Smith, Andrew M; Plumb, Andrew; Rahman, Farooq Z
